Medical Cannabis Patients Lost About 0.5% Symptom Relief Per Session as Tolerance Built Up

Patients experienced a 0.5% decrease in symptom relief per subsequent session (p<0.001). Combustion provided more relief than vaping, eating, or drinking. Higher doses provided greater relief. THC levels were positively associated with relief. Patients increased dose but not THC potency over time. Factors increasing relief also increased side effects. Results were similar for pain, depression, and anxiety.

Fixed effects regression analysis of Releaf App data from 16,395 medical cannabis patients recording 42,005 sessions (120,691 symptom-treatment observations) from 2016-2022. Patients tracked symptoms, products, doses, and relief in real time.

This is the first large-scale measurement of cannabis tolerance in a medical context. The finding that tolerance develops at a consistent rate across symptom types has direct implications for dosing guidance and treatment planning.

The tolerance finding explains why many medical cannabis patients report needing higher doses over time. The trade-off between increasing dose for maintained relief and increasing side effects creates a clinical optimization challenge.

App-based self-report data. Self-selected users of a tracking app may not represent all patients. Cannot verify products or doses. No clinical validation of symptom measures. Observational design. Session count is a proxy for tolerance development.